Compare Eli Lilly And Co (LLY) vs Nutrien Ltd (NTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Nutrien Ltd — how do they compare? Eli Lilly And Co trades at $1,176.52 (market cap $1.04T), while Nutrien Ltd trades at $67.48 (market cap $33.31B). The key difference: Eli Lilly And Co is far larger — about 31.2× Nutrien Ltd's market cap, and Nutrien Ltd pays the higher dividend (3.15%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Nutrien Ltd for 59 Days on average.
| LLY | NTR | |
|---|---|---|
Market Cap | $1.04T | $33.31B |
Volume | 3,064,878 | 1,330,729 |
Sector | Health | Basic Materials |
52-Week High | $1.28K | $83.94 |
52-Week Low | $799.57 | $53.64 |
Typical Hold Time | 93 Days | 59 Days |
Enterprise Value | $1.09T | $45.11B |
Dividend Yield | 0.59% | 3.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Nutrien (NTR) trades at $68.29, down 2.4% today, with a bearish technical signal and mixed earnings history. The stock shows moderate valuation metrics with P/E of 14.14 and P/S of 1.2, while profitability metrics include 8.44% net margin and 9.34% ROE. Recent news highlights industry headwinds from potential Belarus potash imports and an upcoming Investor Day in November 2026.
The outlook remains cautiously optimistic with 60.6% analyst buy ratings and a $76.14 consensus target, though risks include fertilizer price volatility and competitive pressures. Cash flow trends show consistent operational strength but negative net flows in recent years, requiring careful monitoring of debt levels and agricultural market cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
